David M. Goldenberg Sells 20,000 Shares of Immunomedics (IMMU) Stock

Immunomedics (NASDAQ:IMMU) Director David M. Goldenberg sold 20,000 shares of the stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of $17.50, for a total transaction of $350,000.00. Following the completion of the transaction, the director now owns 1,774,285 shares of the company’s stock, valued at $31,049,987.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

IMMU stock traded down $0.69 on Friday, hitting $13.94. 1,608,244 shares of the company’s stock traded hands, compared to its average volume of 2,253,739. Immunomedics has a 1-year low of $5.00 and a 1-year high of $18.93. The firm has a market cap of $2,536.34, a PE ratio of -17.21 and a beta of 1.62. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.26 and a quick ratio of 1.26.

How to Become a New Pot Stock Millionaire

Immunomedics (NASDAQ:IMMU) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.09). The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.90 million. sell-side analysts expect that Immunomedics will post -0.96 earnings per share for the current year.

IMMU has been the subject of several recent analyst reports. BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a report on Thursday, February 22nd. Jefferies Group increased their price objective on shares of Immunomedics from $22.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. TheStreet raised shares of Immunomedics from a “d” rating to a “c-” rating in a research note on Friday, February 9th. ValuEngine raised shares of Immunomedics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research lowered shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Saturday, February 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Immunomedics has an average rating of “Hold” and a consensus price target of $19.00.

Large investors have recently modified their holdings of the stock. Calton & Associates Inc. purchased a new stake in shares of Immunomedics in the 4th quarter valued at approximately $135,000. Xact Kapitalforvaltning AB purchased a new stake in shares of Immunomedics in the 4th quarter valued at approximately $193,000. Raymond James Financial Services Advisors Inc. lifted its position in shares of Immunomedics by 11.4% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 14,400 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 1,473 shares in the last quarter. Sapphire Star Partners LP purchased a new stake in shares of Immunomedics in the 4th quarter valued at approximately $323,000. Finally, SG Americas Securities LLC lifted its position in shares of Immunomedics by 27.2% in the 3rd quarter. SG Americas Securities LLC now owns 26,350 shares of the biopharmaceutical company’s stock valued at $368,000 after acquiring an additional 5,631 shares in the last quarter. Institutional investors and hedge funds own 74.51% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by BBNS and is owned by of BBNS. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://baseballnewssource.com/2018/04/07/insider-selling-immunomedics-inc-immu-director-sells-350000-00-in-stock/2037997.html.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers.

Insider Buying and Selling by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.